Dynakin
The sole provider worldwide combining Model Based Drug Development with GLP Biolab, GCP clinical trial design and execution and product oriented R&D, under the same roof.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2023 | 2024 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 51 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| % profit margin | (3 %) | (13 %) |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Dynakin, founded in 2004 by Dr. Monica Rodriguez Calvo and Dr. Nerea Leal Eguiluz, is a contract research organization (CRO) based in Derio, Spain. In July 2021, the company was acquired by CTI Clinical Trial and Consulting Services, a global, full-service CRO, to enhance CTI's European laboratory services and drug modeling capabilities. Post-acquisition, the founders joined CTI in new integral growth-focused roles.
The company operates as a strategic consulting firm and service provider for the pharmaceutical and biotechnology sectors, offering solutions that span the entire drug development lifecycle, from preclinical research to post-marketing. Dynakin specializes in Model-Based Drug Development (MBDD), utilizing pharmacometric methods to optimize clinical trial design, validate dosing decisions, and minimize development risks and costs. Its clientele includes pharmaceutical and biotechnology companies, research sites, and universities. The business model is service-based, providing contract research and consulting to these entities.
Dynakin integrates several key services under one roof: a Good Laboratory Practice (GLP) certified bioanalytical lab, Good Clinical Practice (GCP) clinical trial services, and product-oriented R&D. The bioanalytical services include method development, assay validation, and specimen analysis for small molecules using liquid chromatography and mass spectrometry (LC-MS/MS). A notable area of expertise is in handling special populations, which led to presenting the first pediatric investigation plan (PIP) to the European Medicines Agency (EMA). The company has also developed DynaPRED®, a web-based platform for personalized pharmacotherapy and treatment individualization.
Keywords: contract research organization, drug development, model-based drug development, pharmacometrics, clinical trials, bioanalytical services, preclinical services, regulatory consulting, PK/PD modeling, pharmaceutical services, biotechnology consulting, pediatric investigation plan, GLP lab, GCP trials, pharmacokinetics, pharmacodynamics, dose optimization, CTI Clinical Trial, translational medicine, clinical research